Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs. The company has clinical supply agreements with Regeneron Pharmaceuticals to evaluate atebimetinib in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell lung cancer; and with Eli Lilly and Company to evaluate atebimetinib in combination with olomorasib in patients with advanced or metastatic KRAS G12C-mutant non-small cell lung cancer. Immuneering Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
| Business Activity | PASS |
| Debt Ratio (0.01%) | PASS |
| Cash Ratio (0.50%) | FAIL |
| Receivables Ratio (0.00%) | PASS |
| Revenue Ratio (0.00%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-13 | -0.27 | Pending | -- |
| 2026-05-15 | -0.25 | -0.21 | +16.7% |
| 2026-03-06 | -0.31 | -0.18 | +42.2% |
| 2025-11-12 | -0.39 | -0.38 | +2.1% |
| 2025-08-13 | -0.40 | -0.40 | -0.5% |
| 2025-05-05 | -0.58 | -0.42 | +28.2% |
| 2025-03-20 | -0.44 | -0.58 | -30.3% |
| 2024-11-13 | -0.55 | -0.49 | +11.2% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | -$13.5M | -$15.2M | — | -$15.3M | -0.21 |
| 2025-12-31 | — | -$11.6M | -$13.7M | — | -$13.8M | -0.18 |
| 2025-09-30 | — | -$15.0M | -$15.3M | — | -$15.4M | -0.38 |
| 2025-06-30 | — | -$14.4M | -$14.7M | — | -$14.8M | -0.40 |
| 2025-03-31 | — | -$15.0M | -$15.4M | — | -$15.5M | -0.42 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-03-13 | NEUFELD LEAH R | Officer | 3,628 | $15.6K |
| 2026-01-16 | BRAKEWOOD HAROLD EUGENE | Officer | 5,250 | $25.0K |
| 2026-01-15 | SCHALL THOMAS J | Director | 21,645 | $101.0K |
| 2026-01-15 | HALL BRETT MATTHEW | Officer | 2,298 | $10.5K |
| 2026-01-13 | NEUFELD LEAH R | Officer | 2,626 | $10.9K |
| 2026-01-12 | FEINBERG PETER | Director | 20,000 | $86.9K |
| 2025-10-03 | FEINBERG PETER | Director | 7,500 | $50.0K |
| 2025-10-01 | BOOKMAN MICHAEL | Officer | 1,020 | $7.0K |
| 2025-10-01 | MORALES MALLORY | Officer | 300 | $1.9K |
| 2025-10-01 | NEUFELD LEAH R | Officer | 800 | $5.1K |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| FMR, LLC | 9.7M | $52.3M | 0.1% |
| Sanofi | 2.7M | $14.6M | 0.0% |
| Vanguard Capital Management LLC | 2.3M | $12.3M | 0.0% |
| Marshall Wace LLP | 2.0M | $10.8M | 0.0% |
| Price (T.Rowe) Associates Inc | 1.8M | $9.9M | 0.0% |
| Blackrock Inc. | 1.5M | $8.1M | 0.0% |
| Millennium Management Llc | 1.1M | $5.9M | 0.0% |
| Geode Capital Management, LLC | 637.9K | $3.4M | 0.0% |
| Occam Crest Management LP | 545.1K | $2.9M | 0.0% |
| Citadel Advisors Llc | 447.3K | $2.4M | 0.0% |
$195.8M
1.59
0.361
6
$3.7M
1.33
12.40
0.2%
53
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.27 | Pending | — |
| 2026-05-15 | $-0.25 | $-0.21 | +16.7% |
| 2026-03-06 | $-0.31 | $-0.18 | +42.2% |
| 2025-11-12 | $-0.39 | $-0.38 | +2.1% |
| 2025-08-13 | $-0.40 | $-0.40 | -0.5% |
| 2025-05-05 | $-0.58 | $-0.42 | +28.2% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($17.00, 6 analysts) | |||
| 10 | $53.80 | +$116.20 (216%) | 14.3R |
| 50 | $269.00 | +$581.00 (216%) | 14.3R |
| 100 | $538.00 | +$1,162.00 (216%) | 14.3R |
- Elevated short interest (12.40 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| NUVL | 0.306 |
| SION | 0.276 |
| LGN | 0.257 |
| ARKG | 0.239 |
| CLDX | 0.237 |
| Ticker | Correlation |
|---|---|
| ELWT | -0.296 |
| UNICAP.KW | -0.127 |
| LMT | -0.118 |
| DGE.L | -0.116 |
| UBL.KA | -0.115 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.